US Patent RE48751 Immunoconjugates with an intracellularly-cleavable linkage
Patent RE48751 was granted and assigned to IMMUNOMEDICS, INC. on September, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+304 characters)
Article
Patent abstract
The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
Edits on 10 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
David M. Goldenberg0
Serengulam V. Govindan0
Sung-Ju Moon0
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent RE048751 Immunoconjugates with an intracellularly-cleavable linkage US Patent RE48751 Immunoconjugates with an intracellularly-cleavable linkage
Infobox
Patent Number
RE0487510
Patent Number
RE487510
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
RE0487510
Date of Patent
September 28, 2021
0Patent Application Number
201812120
Date Filed
December 12, 2018
0Official Website
Edits on 19 May, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 30 Sep, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent RE048751 Immunoconjugates with an intracellularly-cleavable linkage
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
RE048751
Date of patent
September 28, 2021
Patent application number
20181212
Date Filed
December 12, 2018
Find more entities like US Patent RE48751 Immunoconjugates with an intracellularly-cleavable linkage
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
